09/23/2026
Exciting news from Dechra®: Laverdia® (verdinexor tablets) has received full FDA approval.
Laverdia® (verdinexor tablets) is the only FDA-approved oral treatment for canine lymphoma, giving veterinary teams an at-home treatment option that can be used while pet parents consider the next step in their dog’s care.¹,²
From Day 1 through different stages of the cancer journey, Laverdia® helps give veterinary teams another way to keep care moving forward.²,³
Learn more: https://bit.ly/4hih9BI
Package Insert: https://bit.ly/4ro7oqe
References:
1. U.S. Food and Drug Administration. FDA grants full approval of first oral treatment for lymphoma in dogs. Published January 16, 2026. Accessed June 18, 2026. https://www.fda.gov/animal-veterinary/cvm-updates/fda-grants-full-approval-first-oraltreatment-lymphoma-dogs
2. Laverdia® (verdinexor tablets) [prescribing information]. Overland Park, KS: Dechra Veterinary Products LLC; 2026.
3. Sadowski AR, Gardner HL, Borgatti A, et al. Phase II study of the oral selective inhibitor of nuclear export KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res. 2018;14:250. doi:10.1186/s12917-018-1587-9
Important Safety Information: As with all drugs, side effects may occur. For oral use in dogs only. Do not use in dogs that are pregnant, lactating or intended for breeding. Laverdia® (verdinexor tablets) is a possible teratogen, can cause birth defects, and can affect female and male fertility. Laverdia® can cause severe anorexia. Dogs should be carefully monitored for the most commonly reported adverse reactions including inappetence, vomiting, diarrhea, dehydration, weight loss, polyuria, polydipsia, elevated liver enzymes and thrombocytopenia, and supportive care should be provided as clinically indicated. Dogs should be frequently monitored for hematologic and serum chemistry abnormalities. NOT FOR USE IN HUMANS. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. CHILDREN SHOULD NOT COME INTO CONTACT WITH LAVERDIA®. Pregnant women, women who may become pregnant, nursing women and children should not handle or administer Laverdia® or come into contact with the f***s, urine, saliva, or vomit of Laverdia®-treated dogs. Wear protective disposable chemotherapy resistant gloves when handling Laverdia® to prevent direct contact with moistened, broken or crushed tablets and when handling f***s, urine, saliva, or vomit or items that have come in contact with the treated dog during treatment and for 3 days after the last treatment. Refer to the prescribing information for complete details or visit www.dechra-us.com.
This communication may contain information about a product that is otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for you accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.
